China OKs Novo Nordisk's Type-2 diabetes treatment to enter its market

FILE PHOTO: Novo Nordisk hopes to launch experimental obesity drug this decade

BEIJING (Reuters) - China's National Medical Products Administration has granted green lights for Novo Nordisk's insulin icodec injection used for the treatment of Type-2 diabetes among adults to enter the Chinese market, it said on Monday.

(Reporting by Ella Cao and Ryan Woo, Editing by Louise Heavens)